Premium
Cisplatin in recurrent pediatric brain tumors A pog phase II study a pediatric oncology group study
Author(s) -
Sexauer Charles L.,
Khan Atiya,
Burger Peter C.,
Krischer Jeffrey P.,
Van Eys Jan,
Vats Tribhawan,
Ragab Abdelsalam H.
Publication year - 1985
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/1097-0142(19851001)56:7<1497::aid-cncr2820560703>3.0.co;2-7
Subject(s) - medicine , medulloblastoma , cisplatin , ependymoma , toxicity , pediatric oncology , brain tumor , phases of clinical research , oncology , chemotherapy , radiology , cancer , pathology
Forty‐six evaluable pediatric patients with primary recurrent brain tumors resistant to standard therapy were treated with cisplatin, 60 mg/m 2 /day, X2 days every 3 to 4 weeks, to study the efficacy and toxicity of this drug. Complete and partial responses, documented by computed tomography (CT) scan, were demonstrated in 4 of 10 patients with medulloblastoma and 3 of 15 patients with ependymoma. No activity was documented in astrocytic tumors. Dose limiting major toxicities were renal and auditory. It is recommended that the new analogues of cisplatin with less toxicity be studied in these tumors.